question: Which recombinant antibody therapeutics were granted marketing approval in 2014?
answer: Six recombinant antibody therapeutics (vedolizumab, siltuximab, ramucirumab, pembrolizumab, nivolumab, blinatumomab) were granted their first marketing approvals in 2014.